Special Issue "Diagnostic Clinical Spectrometry and Spectroscopy—How to Get It Right"
Deadline for manuscript submissions: 31 August 2020.
Interests: Biomarkers, clinical chemistry: cancer diagnosis, prenatal diagnosis, Haemoglobinopathies, Clinical mass spectrometry, hCG, reproductive endocrinology and fetal antigens
For a minority of human disorder one genetic mutation leading to a single syndrome has been found. Developments in whole genome sequencing has meant that multiple genetic markers in a person’s genome can be detected relatively quickly and cost effectively. However, for the vast majority of common diseases and behavioural traits, the one mutation one attribute hypothesis does not hold true. Although associations can be made for genetic markers and any given disease/disorder/behaviour within large populations, at an individual level most are extremely poor discriminators. Furthermore, deregulation of gene expression can be due to multiple epigenetic events simply undetected by DNA sequencing. Although transcriptomics has attempted to address this deficit - clinically this requires invasive disease tissue, is time consuming, costly and far more complex than originally believed; with the genome/epi-genome to disease phenotype being lost when mechanisms prevent aberrant mRNAs from being translated.
Expressed phenotypic markers are much better clinical indicators of disease status than a genetic susceptibility tests. Many disorders are multi-factorial and consequently multiple different markers are measured; but one at a time. This is time consuming and costly by conventional clinical chemistry technologies.
Emerging, spectroscopic technologies can measure multiple phenotypic marker, or changes in these phenotypic markers simultaneously: be it lipids, metabolites, blood proteins, antibodies or viral particles. With small sample volume and astonishingly fast analysis times these techniques are set to make enormous advances in diagnostic medicine. Clinical mass spectrometry is one such technique which is rapidly being adopted as a new analytical tool in laboratory Medicine, followed by NMR and Raman spectroscopy. To be fully accepted as diagnostic sample test platforms the new approaches require new standards of operating and new understanding—getting it right will hold great rewards.
Prof. Ray Iles
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Multi biomarker/antigen profiling
- Strong clinical disease association-diagnosis
- Minimal to non-invasive sampling
- Clinical Mass spectrometry
- Clinical Raman Spectroscopy
- Clinical NMR spectroscopy